ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Angion Biomedica, Sinovant Sciences collaborate to develop BB3
biospectrumasia
November 19, 2018Angion is currently developing BB3 in a Phase 3 trial for the treatment of delayed graft function (DGF) following kidney transplantation and in a Phase 2 trial for the treatment of acute kidney injury (AKI) following open-heart surgery requiring cardiopul
Pharma Sources Insight July 2025
